RE:NEWS OUT !! Positive news for TBP, given that it is a revenue stream that is much more readily accessible in comparison to their orphan drugs (which continue down the pipeline to development, approval, and finally commercialization).
They have a solid strategy for it too. The natural health products (NHP) will be managed through the company's agro tek subsidiary which is focused on acquiring, manufacturing and distributing natural health products containing cannabis and other non-psychoactive cannabinoids. Its NHP pipeline includes product for pain management, cardiovascular disease prevention, athletic performance, and well-being, among others. TBP is targeting both Canada and the US supplement, over the counter markets. AGTK intends to acquire formulations and established brands with the goal of integrating its cannabis R&D into the less regulated NHP market. This annoucement ensures that we have leadership at the helm that can accomplish that.
The Company also has a strong pipeline of natural health products that includes AGT001, a topical product for pain management; AGT002 product lineoral for cardiovascular disease prevention, athletic performance, and wellbeing; AGT003 product line for skin care; AGT004 for womenquality of life.
Take for example the CBD clinic, they have been operating and offering theratputic products containing CBD for quite a while already. They are steadily increasing. NHP is lucrative and it is a market that is big for us.
Their extension research into cannabis, will help their partners develop these NHP. take for example, how PPP005's formulation will assist in providing creams for chronic pain, currently working with genacol.
https://tetrabiopharma.com/investors/press-releases/press-release-details/2018/Genacol-Canada-Corporation-and-Tetra-Bio-Pharma-Team-Up-to-bring-Innovative-Cannabinoid-Treatments-to-Self-Care-Market-in-Canada/default.aspx
LONG. ignore the rest.